Subtype
Ocular Melanoma
CI-CAN-00001295Explore in graph →
62 active trials1 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001295Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (36)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05402059 | Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice(ISABELLA) | unknown | — | 1,570 | MelanomaPRO, RussiaOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT02376920 | 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes(CLEAR) | completed | — | 93 | Castle Biosciences IncorporatedINDUSTRY |
| 0 |
| May 16, 2022 |
| clinicaltrials |
| NCT00084656 | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma | completed | Phase 2 | 77 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 14, 2022 | clinicaltrials |
| NCT02626962 | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma(GEM1402) | completed | Phase 2 | 52 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT01460810 | Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma | completed | N/A | 20 | University of Colorado, DenverOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT01930968 | Definity for Ultrasound of Intraocular Tumors | withdrawn | — | 0 | Emory UniversityOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04960891 | A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp(Non Applicable) | available | — | — | Immunocore LtdINDUSTRY | 0 | Jan 21, 2022 | clinicaltrials |
| NCT05179174 | The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma | unknown | — | 102 | University of CataniaOTHER | 2 | Jan 5, 2022 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT02129075 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05047276 | Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma(PULSE-UM) | unknown | Phase 1 / Phase 2 | 16 | José María Piulats RodríguezOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT00324727 | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma | completed | Phase 3 | 93 | Delcath Systems Inc.INDUSTRY | 1 | Jun 21, 2021 | clinicaltrials |
| NCT02913417 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | unknown | Phase 1 / Phase 2 | 26 | David Minor, MDOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT00344799 | Cytogenetic Study of Ocular Melanoma | completed | — | 95 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT01430416 | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | completed | Phase 1 | 153 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT04577742 | Uveal Melanoma and Brachytheraphy: Long-term Outcomes. | completed | — | 350 | Federico II UniversityOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT02771340 | Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma | completed | Phase 1 | 10 | Iconic Therapeutics, Inc.INDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT02363283 | Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02336763 | Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases | terminated | N/A | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04184518 | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma(CEDUVEAL-M) | withdrawn | Phase 2 | 0 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT01413191 | Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2020 | clinicaltrials |
| NCT03022565 | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | withdrawn | Early Phase 1 | 0 | University of MiamiOTHER | 0 | Feb 6, 2020 | clinicaltrials |
| NCT02158520 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 24 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT01551459 | A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma(SUAVE) | completed | Phase 2 | 124 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Oct 29, 2019 | clinicaltrials |
| NCT02359851 | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | terminated | Phase 2 | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01471054 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | terminated | Phase 2 | 6 | Arman MashayekhiOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00346372 | Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy | terminated | — | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 12, 2019 | clinicaltrials |
| NCT02909517 | The Role of Inflammation in Ocular Tumours | unknown | — | 30 | Unity Health TorontoOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT01100528 | Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance | completed | Phase 2 | 38 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00121225 | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 2 | Jan 29, 2019 | clinicaltrials |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | terminated | Phase 1 / Phase 2 | 23 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT01200238 | STA-9090(Ganetespib) in Metastatic Ocular Melanoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00243061 | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT01961115 | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00450255 | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | May 24, 2018 | clinicaltrials |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT01893099 | Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma | completed | Phase 1 | 11 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 12, 2017 | clinicaltrials |
| NCT01034787 | Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma | completed | Phase 2 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT01252251 | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01143402 | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2017 | clinicaltrials |
| NCT00471471 | Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 22 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00680225 | Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma | completed | Phase 3 | 10 | New England Retina AssociatesOTHER | 1 | Apr 12, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jun 15, 2022source: clinicaltrials